UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 6, 2022

OCUGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-36751 (Commission File Number)

04-3522315 (I.R.S. Employer Identification Number)

263 Great Valley Parkway Malvern, Pennsylvania 19355 (484) 328-4701

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:				
Title of each class Trading Symbol(s) Name of each exchange on which registered				
Common Stock, \$0.01 par value per share	OCGN	The Nasdaq Stock Market LLC		
		(The Nasdaq Capital Market)		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2022, Ocugen, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2022. The Company has scheduled a conference call and webcast for 8:30 a.m. eastern time on May 6, 2022 to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the Company's website at www.ocugen.com. Copies of the press release and presentation materials are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

The information disclosed under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing

Item 8.01 Other Events.

Attached as Exhibit 99.3 and incorporated herein by reference is a presentation that the Company will post on its website on May 6, 2022 and may use from time to time in presentations or discussions with investors, analysts, and other parties.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are being filed or furnished (as applicable) herewith:

(d) Exhibits

Exhibit No.	Document
99.1	Press Release of Ocugen, Inc. dated May 6, 2022.
99.2	Earnings Release Presentation issued May 6, 2022.
99.3	Ocugen, Inc. Presentation.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2022

OCUGEN, INC.

By: /s

/s/ Shankar Musunuri Name: Shankar Musunuri Title: Chief Executive Officer and Chairman

Ocugen Provides Business Update and First Quarter 2022 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET

• OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB Review

• Ocugen's exclusive territory for COVAXIN™ (BBV152) marketing expanded to include all of North America

MALVERN, Pa. — May 6, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today reported first quarter 2022 financial results along with a general business update.

"We've made significant progress this quarter across multiple areas and we remain confident in the long-term opportunities and growth that we believe our pipeline will unlock" said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "I am very proud of our dedicated team for moving our breakthrough gene therapy into the clinic and for their commitment to advancing COVAXINTM to fight against COVID-19."

Business Updates

- OCU400 Clinical Trial The Company achieved a key milestone in its Phase 1/2 clinical trial for OCU400 of "first patient, first dose" in late March 2022. The Data and Safety Monitoring Board for the clinical trial reviewed safety data based on dosing to date and recommended that the study proceed with enrolling the remaining study subjects in the current cohort at the target dose level. A second patient was dosed in May 2022.
- COVAXINTM Rights Expanded to include Mexico In April 2022, the Company expanded its rights to develop, manufacture, and commercialize COVAXINTM to include Mexico, where the vaccine is already authorized for
 emergency use in adults and is currently under review by local regulators for emergency pediatric use. The company is now working on commercializing the vaccine in Mexico. The Company's exclusive territory for
 COVAXINTM now encompasses the entire North American region.
- COVAXINTM in the United States The Company is actively engaged in discussions with the U.S. Food and Drug Administration (the "FDA") to address its questions and resume the Company's Phase 2/3 immuno-bridging and broadening clinical trial for COVAXINTM, OCU-002. In addition, the Company intends to continue working with the FDA to finalize the additional studies required for a Biologies License Application ("BLA").
- COVAXINTM in Canada Discussions with Health Canada regarding COVAXINTM are ongoing. The Company is in discussions with Canadian officials regarding financial support for the potential acquisition of a
 manufacturing facility in Belleville, Ontario, Canada that would be transformed to become a manufacturing and research and development hub to support both the Company's current and future product candidate pipeline.
- Organizational Growth Nearly 20 employees joined Ocugen in the first quarter to fill key roles that support operational needs, including clinical trials and regulatory milestones. The number of employees now totals 79.
- Addition to the Board of Directors In March 2022, Marna C. Whittington, Ph.D., former Chief Executive Officer of Allianz Global Investors Capital, joined the Company's Board of Directors. Dr. Whittington is a renowned financial sector leader and her experience and expertise will be exceedingly important to the Company's growth strategy.

First Quarter 2022 Financial Results

- The Company's cash, cash equivalents, and restricted cash totaled \$129.9 million as of March 31, 2022, compared to \$95.1 million as of December 31, 2021. The Company had 215.6 million shares of common stock outstanding as of March 31, 2022.
- Research and development expenses for the three months ended March 31, 2022 were \$7.9 million compared to \$2.9 million for the three months ended March 31, 2021. General and administrative expenses for the three months ended March 31, 2022 were \$10.1 million compared to \$4.2 million for the three months ended March 31, 2021. Ocugen reported a \$0.09 net loss per share for the three months ended March 31, 2022 compared to a \$0.04 net loss per share for the three months ended March 31, 2021.

Conference Call and Webcast Details

Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business updates. Ocugen's senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

The call can be accessed by dialing (844) 873-7330 (U.S.) or (602) 563-8473 (international) and providing the conference ID 6995784. To access a live audio webcast of the call on the "Investors" section of the Ocugen website, please click here. A replay of the webcast will be archived on Ocugen's website for approximately 45 days following the call.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements about Ocugen's progress in advancing the review of COVAXINTM and its other product candidates with the FDA, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endors and the other of an endors in a state of the other other other of the other provided responses that are currently under review by Health Canada; the risk that Ocugen may not be able to successfully commercialize COVAXINT^M in Mexico for adults over the age of 18 pursuant to Ocugen's agreement with Bharat Biotech and the risk that Ocugen does not obtain emergency pediatric use for COVAXINTM in Mexico for children between two and 18 years of age on a timely basis, if at all; the risk that the FDA does not lift the clinical hold on Ocugen's Phase 2/3 immuno-bridging and broadening clinical trial for COVAXINTM on a timely basis, if at all; risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data is subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech's clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from the preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India, will be accepted by regulatory authorities or otherwise sufficient to support Ocugen's submissions for regulatory approvals or authorizations in the United States, Canada or Mexico; the size, scope, timing and outcome of any additional clinical trials or studies that Ocugen may be required to conduct to support regulatory approvals or authorizations; any additional chemistry, manufacturing, and controls information that Ocugen may be required to submit to regulatory authorizations; any additional chemistry, manufacturing, and controls information that Ocugen may be required to submit to regulatory authorizes; whether and when a BLA for COVAXINTM will be submitted to or approved by the FDA; the risk that Ocugen may not be able to successfully negotiate and execute definitive transaction agreements for the acquisition of the manufacturing site on acceptable terms, if at all, and the ultimate terms and timing for closing of the transactions contemplated thereby; the risk that Ocugen will not be able to successfully close the acquisition of the manufacturing site; risks associated with the planned development and refurbishing of the manufacturing site, including that the expected costs for such development may be greater than currently contemplated or that the planned development may take longer than expected or fail to be completed on a timely basis, if at all; and the risk that Ocugen will not be able to scale production for such manufacturing site to adequately support manufacturing of its product candidates or the other products that may in the future be manufactured at such manufacturing site; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, Mexico or other jurisdictions; market demand for COVAXINTM in the United States, Canada or Mexico; decisions by the regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXINTM in the United States, Canada or Mexico, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in Ocugen's periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in

the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Ocugen Contact: Ken Inchausti Head, Investor Relations & Communications +1 484 237 3398 ken.inchausti@ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

(tables to follow)

OCUGEN, INC. CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited)

	М	larch 31, 2022	December 31, 2021	
Assets				
Current assets				
Cash and cash equivalents	\$	129,771 \$	94,958	
Prepaid expenses and other current assets		8,256	7,688	
Total current assets		138,027	102,646	
Property and equipment, net		1,921	1,164	
Restricted cash		151	151	
Other assets		1,628	1,800	
Total assets	\$	141,727 \$	105,761	
Liabilities and stockholders' equity				
Current liabilities				
Accounts payable	\$	3,896 \$	2,312	
Accrued expenses		3,537	4,325	
Operating lease obligations		254	363	
Total current liabilities		7,687	7,000	
Non-current liabilities				
Operating lease obligations, less current portion		1,180	1,231	
Long term debt, net		1,731	1,712	
Total liabilities		10,598	9,943	
Stockholders' equity				
Convertible preferred stock		1	1	
Common stock		2,158	1,995	
Treasury stock		(48)	(48)	
Additional paid-in capital		278,704	225,537	
Accumulated deficit		(149,686)	(131,667)	
Total stockholders' equity		131,129	95,818	
Total liabilities and stockholders' equity	\$	141,727 \$	105,761	

OCUGEN, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) (Unaudited)

	Three months ended March 31,		
	 2022	2021	
Operating expenses			
Research and development	\$ 7,915 \$	2,872	
General and administrative	10,119	4,185	
Total operating expenses	18,034	7,057	
Loss from operations	(18,034)	(7,057)	
Other income (expense), net	15	(20)	
Net loss and comprehensive loss	\$ (18,019) \$	(7,077)	
Shares used in calculating net loss per common share — basic and diluted	 205,693,498	186,298,122	
Net loss per share of common stock — basic and diluted	\$ (0.09) \$	(0.04)	




Forward Looking Statement

on Reform Act of 1995, which are subject to risks and uncertainties. Ocugen may, in some cases, use ates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of rms such as "predicts," "believes," "potential," "proposed," "continue," "estir future events or outcomes to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements about Ocugen's progress in advancing the review of COVAXINTM and its other product candidates with the FDA, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, ability to timely enroll clinical trial participants, commence mpletion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates; the risk that Health Canada does not accept its New Drug Submission ("NDS") for and/or o COVAXINTM or that Ocugen may not be able to adequately resolve the deficiencies noted by Health Canada with respect to its NDS, for which Ocugen has provided responses that are currently under review by Health Canada; the risk that Ocugen may not be able to successfully commercialize COVAXINTM in Mexico for adults over the age of 18 pursuant to Ocugen's agreement with Bharat Biotech and the risk that Ocugen does not obtain emergency pediatric use for COVAXINTM in Mexico for children between two and 18 years of age on a timely basis, if at all; the risk that the FDA does not lift the clinical hold on Ocugen's Phase 2/3 immuno-bridging and broadening clinical trial for COVAXINT^M on a timely basis, if at all; risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data is subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities, whether and when data from Bharat Biotech's clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from the preclinical and clinical studies of COVAXINTM, which have been conducted by Bharat Biotech in India, will be accepted by regulatory authorities or otherwise sufficient to support Ocugen's submissions for regulatory approvals or authorizations in the United States, Canada or Mexico; the size, scope, timing and outcome of any additional clinical trials or studies that Ocugen may be required to conduct to support regulatory approvals or authorizations; any additional chemistry, manufacturing, and controls information that Ocugen may be required to submit to regulatory authorities ; whether and when a BLA for COVAXINTM will be submitted to or approved by the FDA; the risk that Ocugen may not be able to successfully negotiate and execute definitive transaction agreements for the acquisition of the manufacturing site on acceptable terms, if at all, and the ultimate terms and timing for closing of the transactions contemplated thereby; the risk that Ocugen will not be able to successfully close the acquisition of the manufacturing site; risks associated with the planned development and refurbishing of the manufacturing site; including that the expected costs for such development may be greater than currently contemplated or that the planned development may take longer than expected or fail to be completed on a timely basis, if at all; and the risk that Ocugen will not be able to scale production for such manufacturing site to adequately support manufacturing of its product candidates or the other products that may in the future be manufactured at such manufacturing site; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, Mexico or othe iurisdictions; market demand for COVAXINTM in the United States, Canada or Mexico; decisions by the regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXINTM in the United States, Canada or Mexico, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in Ocugen's periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this presentation speak only as of the date of this presentation. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this presentation whether as a result of new information, future events, or otherwise, after the date of this presentation.





Business update on COVAXIN™ (BBV152)




The Company is working with the FDA to address questions arising from WHO's inspection of BBIL's manufacturing facility in order to continue with OCU-002 clinical trial

Planning to commercialize COVAXIN™ in Mexico in 2022, following the broadening of the Ocugen Territory which now covers all of North America

Teams are poised for continuing OCU-002 once path forward is clarified with regulators

Business update on the Ophthalmology Portfolio



ocugen

First and second patients dosed in Phase 1/2 clinical trial studying OCU400 for the treatment of retinitis pigmentosa resulting from genetic mutations of *NR2E3* and *RHO*

Data Monitoring and Safety Board recommended OCU400-101 clinical trial to proceed with enrolling the remaining study subjects in the current cohort at the target dose level

OCU410 initiating IND-enabling studies to support a future Phase 1/2 clinical trial



Financial Update

Statement of Operations	Three months ei	Three months ended March 31,		
Statement of Operations	2022	2021		
Research and development expense	\$7.9	\$2.9		
General and administrative expense	10.1	4.2		
Net loss	\$(18.0)	\$(7.1)		
Net loss per share of common stock – basic and diluted	\$(0.09)	\$(0.04)		


Balance Sheet Data	March 31, 2022	December 31, 2021
Cash, cash equivalents, and restricted cash	\$129.9	\$95.1
Debt	\$1.7	\$1.7
Shares outstanding	215.6	199.4

Unaudited; in millions, except per share amounts









Forward Looking Statement

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," (might," "will," should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, including the risk that such dates are not met due to impacts from the ongoing COVID-19 pandemic, as well as risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bha Biotech's clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from preclinical and clinical studies of COVAXIN™. which have been conducted by Bharat Biotech in India, will be accepted by the U.S. Food and Drug Administration ("FDA") or otherwise sufficient to support our Investigational New Drug applications ("IND") or planned Biologics License Applications ("BLA"), as applicable; whether and when we are able to resolve the clinical hold on our Phase 2/3 immuno-bridging and broadening clinical trial for COVAXIN[™]; the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support a for COVAXIN[™], including our Phase 2/3 immuno-bridging and broadening clinical trial and planned safety-bridging clinical trial; any additional chemistry, manufacturing, and controls information that we may be required to submit; whether and when a BLA for COVAXIN[™] will be submitted to the FDA; whether and when a BLA may be approved by the FDA, whether a New Drug Submission application may be approved by Health Canada, and whether th additional information that we provide to Health Canada will be sufficient to support an approval by Health Canada of COVAXIN[™] and any delays associated therewith; our ability to successfully commercialize COVAXIN[™] in Mexico for adults over the age of 18 pursuant to our agreement with Bharat Biotech, and whether and when we will obtain Emergency Use Authorization approval for COVAXINIM in Mexico for children between 2 and 18 years of age; the authorizations or approvals will depend on myriad factors, including making a determination as to whether the vaccine candidate's benefits outweigh its known risks and determination of the vaccine candidate's efficacy and, if authorized or approved, whether it will be commercially successful; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, Mexico or other jurisdictions; manufacturing capabilities, manufacturing capacity, and supply restrictions, including whether sufficient doses of COVAXIN[™] can be manufactured or supplied within our projected time periods; market demand for COVAXIN[™] in the United States, Canada or because the second could affect the availability or commercial potential of COVAXIN[™] in the United States, Canada or Mexico, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of this presentation. Except as required by law, w assume no obligation to update forward-looking statements contained in presentation whether as a result of new information, future events, or otherwise, after the date of this presentation.



We're Here to Make an Impact Through *Courageous Innovation*

Mission

At Ocugen, we are developing novel solutions to medical challenges, approaching healthcare innovation with purpose and agility to deliver new options for people facing disease.

Vision

We are fostering a future where no one feels hopeless in the face of disease. From genetic disorders to new diseases, our expertise and tenacity are creating choices – for people and for global communities.



Pioneering a breakthrough modifier gene therapy for several genetic forms of vision impairment

Innovating a novel biologic to treat eye diseases that can lead to vision loss for millions of people

Co-developing a COVID-19 vaccine



Pipeline Overview

Asset/P	Mail Indication	X Status
COVAXIN™ (BBV Whole-Virion Inactivated Vacci	COVID-19	 EUA for adults in Mexico; EUA for 2–11 year olds under review* US Phase 2/3 clinical trial* (Temporar paused dosing/clinical hold) Health Canada NDS under review*
	Gene mutation-associated retinal degenerat	tion**
	NR2E3 Mutation	Phase 1/2
ne OCU400 *** AAV-hNR2E3	RHO Mutation	Phase 1/2
tform	CEP290 Mutation	To be submitted
OCU410 AAV-hRORA	PDE6B Mutation	To be submitted
	Dry Age-Related Macular Degeneration (Dry A	AMD)** Preclinical
	Diabetic Macular Edema	Preclinical
gic OCU200 Transferrin – Turr	Diabetic Retinopathy	Preclinical
	Wet Age-Related Macular Degeneration (Wet	t AMD) Preclinical
l on Bharat Biotech-sponsored clinical trials in poroved therapies exist /www.aao.org/eye-health/diseases/retinitis-pi	Wet Age-Related Macular Degeneration (Wet PHAN DRUG DESIGNATION in the US; Broad ORPHAN MEDICINAL PRODUCT congenital amaurosis (LCA) int https://www.aao.org/eye-health/diseases/amd-treatment	





Why COVAXIN[™] (BBV152)? Designed to augment our North American arsenal of vaccines against COVID-19

RESULTS SHOW PREVENTION OF

 Phase 3 data suggest prevention of hospitalizations caused by COVID-19 Booster dose provides robust neutralizing antibody responses

against Omicron and Delta variants

10 dose vial that can be stored and shipped at 2°- 8° C with a 2-year shelf life and 6-month stability at room

SEVERE COVID-19 DISEASE

TRANSPORTATION

temperature

AND STORAGE EASE

DESIGNED FOR BROAD SPECTRUM IMMUNE RESPONSE

- Adult and pediatric phase 2/3 data suggest both humoral & cellular responses generated against multiple viral proteins
- Data support that the vaccine induces a Th1 response (cell-mediated immunity) which can be vital for durable protection

KNOWN SAFETY PROFILE USING VERO CELL PLATFORM


 Data demonstrate strong safety profile
 within adult and pediatric populations Technology platform used to produce Polio, Influenza and Rabies vaccines







Why COVAXIN[™] (BBV152)? Phase 3 Clinical Trial Highlights



Pathway for COVAXIN™ (BBV152) development



MODIFIER GENE THERAPY PLATFORM

Breakthrough technology designed to address many rare diseases as well as complex diseases that affect millions

ocugen

Our Focus: Nuclear Hormone Receptor Genes (NHRs)


NHRs are modulators of retinal development & function, acting as "master genes" in the retina

Molecular reset of key transcription factors and associated gene networks – retinal homeostasis



Gene modifier concept including, its impact on clinical phenotypes, is well known in other disease areas, such as cystic fibrosis and spinal muscular atrophy





Our Vision: Modifier Gene Therapy vs Traditional Gene Augmentation

Gene Augmentation: Tran target cells.	cell cell GENE X retoring give X	cell GENEX	of many genes, gene-netwo Modifier gene M Cell Cell GENEX	rks and regulate basic biologics	al gene to modify the expression of dessess using the same Modifier Cane product.
Traditional Gene Therapy	ONE Disease		OCU400	NR2E3 Mutation-Associated Retin Rhodopsin Mutation-Associated R CEP290 Mutation-Associated Retin PDE6B Mutation-Associated Retin	Petinal Disease Spectruy for a point of the second
Traditional approach that targets one individual gene mutation at a time	Regulatory pathway focused on specific product for one disease	Longer time to recoup development costs	Novel approach that targets nuclear hormone genes (NHRs), which regulate multiple functions within the retina	Smoother regulatory pathway due to ability to target multiple diseases with one product	Ability to recoup development costs over multiple therapeutic indications
ocugen.					12

Our Proof of Principle: Published in Nature Gene Therapy







Protection elicited in multiple animal models of degeneration caused by different mutations




Potential to represent first broad-spectrum therapy and to provide rescue even after disease onset

natureresearch


articles/s41434-020-0134-z

OCU400 - Pathway to Phase 3 Clinical Trials

Just 30 days to receive FDA clearance for Phase 1/2 gene therapy clinical trial



Summary of activities at Ocugen



Experienced Leadership









Shankar Musunuri, PhD, MBA Chairman, CEO, & Co-Founder

Jessica Crespo, CPA Chief Accounting Officer & SVP, Finance

Bruce Forrest, MD Acting Chief Medical Officer

J.P. Gabriel SVP, Technical Operations



Arun Upadhyay, PhD SVP, Research & Development

AVP, Human Resources, Chief of Staff

ocugen.

Zara Gaudioso, SHRM-CP

Nirdosh Jagota, PhD SVP, Regulatory Affairs, Compliance and Safety

Huma Qamar, MD, MPH, CMI AVP, Clinical Development

Mike Shine SVP, Commercial

21

